The major role of clinicians in the discovery of off-label drug therapies

Pharmacotherapy

Volumn 26, Issue 3, 2006, Pages 323-332

  DeMonaco, Harold J ^a,b   Ali, Ayfer ^c   Von Hippel, Eric ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Lead users; New molecular entities; Off label drug use; Prescription drugs

Indexed keywords

ABACAVIR; BOTULINUM TOXIN A; BRINZOLAMIDE; CANDESARTAN; CAPECITABINE; CELECOXIB; CITALOPRAM; EFAVIRENZ; EPTIFIBATIDE; FOMIVIRSEN; LEFLUNOMIDE; LEPIRUDIN; LOTEPREDNOL ETABONATE; MONTELUKAST; NARATRIPTAN; PARICALCITOL; PROPOFOL; RECOMBINANT THYROTROPIN; RIFAPENTINE; RISEDRONIC ACID; RIZATRIPTAN; SEVELAMER; SILDENAFIL; TELMISARTAN; THALIDOMIDE; TIROFIBAN; TOLCAPONE; TOLTERODINE; UNINDEXED DRUG; VALRUBICIN;

ARTICLE; CLINICAL PRACTICE; DRUG APPROVAL; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; PATENT; PHYSICIAN; PRESCRIPTION;

BOTULINUM TOXIN TYPE A; COSMETICS; DERMATOLOGIC AGENTS; DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; HUMANS; PHARMACEUTICAL PREPARATIONS; PHYSICIANS; PRODUCT SURVEILLANCE, POSTMARKETING; PROPOFOL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33644685442     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.3.323     Document Type: Article

References (29)

1. Jong WT, Vulto A, deHoog M, Schimmel KJ, Tibboel D, van den Anker JN. Unapproved and off label use of drugs in a children's hospital [letter]. N EnglJ Med 2000;343:1125.
2. Poole SG, Dooley MJ. Off-label prescribing in oncology. Support Care Cancer 2004;12:302-5.
3. Urban GL, von Hippel E. Lead user analyses for the development of new industrial products. Manage Sci 1988;34:569-82.
4. Herstatt C, von Hippel E. From experience: developing new product concepts via the lead user method: a case study in a "low tech" field. J Prod Innovation Manage 1992;9:213-22.
5. Morrison PD, Roberts JH, von Hippel E. Determinants of user innovation and innovation sharing in a local market. Manage Sci 2000;46:1513-27.
6. Franke N, von Hippel E. Satisfying heterogeneous user needs via innovation toolkits: the case of Apache security software. Res Policy 2003;32:1199-215.
7. Lüthje C. Customers as co-inventors: an empirical analysis of the antecedents of customer-driven innovations in the field of medical equipment. Presented at the 32nd conference of the European Marketing Academy (EMAC), Glasgow, Scotland, May 20-23, 2003.
8. Lüthje C. Characteristics of innovating users in a consumer goods field: an empirical study of sport-related product consumers. Technovation 2004;24(9):683-95.
9. Franke N, Shah S. How communities support innovative activities: an exploration of assistance and sharing among end-users. Res Policy 2003;32:157-78.
10. Lüthje C, Herstatt C, von Hippel E. The dominant role of local information in user innovation: the case of mountain hiking [working paper no. 4377-02]. Cambridge, MA: Massachusetts Institute of Technology-Sloan School of Management, 2002.
11. Riggs W, von Hippel E. The impact of scientific and commercial values on the sources of instrument innovation. Res Policy 1994;23(4):459-69.
12. Ogawa S. Does sticky information affect the locus of innovation? Evidence from the Japanese convenience-store industry. Res Policy 1998;26:777-90.
13. von Hippel E. Democratizing innovation. Cambridge, MA: MIT Press, 2004.
14. Raymond ES. The cathedral and the bazaar. In: The cathedral and the bazaar musings on Linux and open source by an accidental revolutionary (revised ed). Sebastopol, CA: O'Reilly, 2001:19-64.
15. Brooks PF Jr. The mythical man-month: essays on software engineering. Reading, MA: Addison-Wesley Publishing Company, 1979.
16. Allergan Inc. Botox Cosmetic (botulinum toxin type A) package insert. Irvine, CA; 2002.
17. Allergan Inc. Annual shareholders report 2003. Irvine, CA; 2003.
18. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A. exotoxin. J Dermatol Surg Oncol 1992;18:17-21.
19. Zeneca Pharmaceuticals. Diprivan (propofol) package insert. Wilmington, DE; 1989.
20. Borgeat A, Wilder-Smith OH, Saiah M, Rifat K. Subhypnotic doses of propofol relieve pruritus induced by epidural and intrathecal morphine. Anesthesiology 1992;76:510-12.
21. Rosenberg JM, Koumis T, Nathan JP, et al. Current status of pharmacist-operated drug information centers in the United States. Am J Health-Syst Pharm 2004;61:2023-32.
22. Kos M, Wertheimer A, Mrhar A. Satisfaction with pharmacotherapy for approved and off-label indications: a Delphi study. Ann Pharmacother 2005;39:649-54.
23. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-2.
24. Brodell RT. Do more than discuss that unusual case: write it up. Postgrad Med 2000;108:19-20, 23.
25. Aronson JK. Anecdotes as evidence [editorial]. BMJ 2003;326:1346.
26. Hunter KM. Doctor's stories: the narrative structure of knowledge. Princeton, NJ: Princeton University Press, 1991.
27. Little M. Talking cure and curing talk. J R Soc Med 2005;98:210-12.
28. Kellerman SE, Herold J. Physician response to surveys: a review of the literature. Am J Prev Med 2001;20:61-7.
29. Wurtman RJ, Bittiker RL. The slowing of treatment discovery, 1965-1995. Nat Med 1995;1(11):1122-5.